ASRAS

This asset is not currently listed on any markets available through Pearler. The information on this page may be inaccurate or out of date.

Asset Logo

🇦🇺 ASX

👑 Overview

📈 Performance

💵 Cost

🍃 Esg

🤓 Advanced

👨‍👩‍👧‍👦 Community

📈

N/A
Annual Growth

5 years average annual growth

💵

$ 500
Minimum Order

Due to regulatory requirements

🌏

8
Pearlers Invested

Since January 2020

👑 Overview

Key information
🔎 Fund Overview

Asra Minerals Limited - Option Expiring 02-Sep-2027 Deferred

📈 Performance

Price History

N/A

1M

All Time

Graph

Table

empty share chartempty share line

Performance graph isn't available yet for this share

Unsure how much or often to invest?
🗓️ Investing frequency calculator

Determine the investment frequency needed to reach your goals

Try it out →
💵 Investing amount calculator

Determine the recurring investment needed to reach your goals

Try it out →
⏱️ Investing duration calculator

Determine how long you will need to invest to reach your goals

Try it out →

💵 Costs

💵

6.50 AUD*
Purchase Fee

*$5.50 with Pearler Prepay

💼

N/A
Management Fee

Included in unit price, not charged by Pearler

💸

Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator

🤓 Advanced information

Technical Info

👩‍👩‍👦 Community Insights

How our community is investing

🌏 Pearlers invested in ASRAS

8

📊 Total Capital Earnings

N/A

🔃 Average investment frequency

N/A

💵 Average investment amount

N/A

Last time a customer invested in ASRAS

N/A
ASRAS investor breakdown
💵 Income of investors

More than 200k

150k - 200k

100k - 150k

20%

50k - 100k

33%

Less than 50k

47%
👶 Age of investors

18 - 25

13%

26 - 34

38%

35 - 90

50%
🙋 Legal gender of investors

Female

50%

Male

50%

Pearlers who invest in ASRAS also invest in...

Asra Minerals Limited

ASR

Asra Minerals Ltd. engages in the development and exploration of mineral properties. The company is headquartered in Perth, Western Australia. The firm is focused on targeting a growing gold, lithium and rare earth element (REE) portfolio in the premier Goldfields region of Western Australia. The Company’s flagship Mt Stirling Project is located 240 kilometers (km) north of Kalgoorlie and hosts 10 gold prospects, and a gold JORC Mineral Resource. The project also has a potential for REE and critical minerals including scandium. Its Kookynie West Project is situated less than 50km south, which is an underexplored site showing gold, lithium and REE potential. The company also has two lithium-focused exploration projects in the southern Yilgarn area of Western Australia at Lake Johnston and Lake Cowan, located in highly prospective ground between operating lithium mines at Earl Grey and Bald Hill. Its footprint in the Eastern Goldfields region stands at approximately 1,134 square kilometers (km2).

🙌 Performance (5Yr p.a)

-14.05%

📊 Share price

$0.00 AUD

⛏️ MINING

Find Out More

📊 Share price

$0.04 AUD

Pilbara Minerals Ltd. engages in the exploration and evaluation of mineral properties. The company is headquartered in Perth, Western Australia and currently employs 768 full-time employees. The company went IPO on 2007-09-19. The firm is primarily engaged in the exploration, development, and mining of minerals in Australia. Its 100% owned Pilgangoora hard-rock lithium operation is located approximately 120 kilometers (kms) from Port Hedland in Western Australia’s resource-rich Pilbara region. The operation consists of two processing plants: the Pilgan Plant, located on the northern side of the Pilgangoora area and produces spodumene and tantalite concentrates, and the Ngungaju Plant is located to the south produces spodumene concentrate. The company owns 70% of the Mt Francisco project, which is located 50 km south-west of the Pilgangoora Project and hosts the large occurrence of outcropping pegmatites located nearby to Port Hedland. The company is also pursuing a proposed downstream joint venture (JV) for the development of an approximately 43,000 tons per annum (tpa) lithium carbonate equivalent (LCE) lithium chemical conversion facility in South Korea.

🙌 Performance (5Yr p.a)

149.49%

📊 Share price

$3.00 AUD

⛏️ MINING

Actinogen Medical Ltd. is a clinical stage Australian biotechnology company, which focuses on the development of novel treatments or cognitive impairment associated with neurological, psychiatric, and metabolic diseases due to raised cortisol. The company is headquartered in Sydney, New South Wales. The company went IPO on 2007-10-16. The firm is engaged in the development of a therapy for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol. The firm is engaged in the development of its lead compound, Xanamem, as a therapy for Alzheimer’s Disease, Major Depressive Disorder, Fragile X Syndrome, and other neurological diseases where reducing cortisol inside brain cells could have a positive impact. Xanamem’s mechanism of action is to block the production of cortisol inside cells through the inhibition of the 11B-HSD1 enzyme in the brain. Xanamem is designed to get into the brain after it is absorbed in the intestines upon swallowing its capsule. The company has studied 11B-HSD1 inhibition by Xanamem in approximately 300 volunteers and patients. The firm conducts a series of Phase II studies in multiple diseases to further confirm and characterize Xanamem’s therapeutic potential.

🙌 Performance (5Yr p.a)

-5.42%

📊 Share price

$0.03 AUD

🧬 BIOTECHNOLOGY

Invion Ltd. is a clinical-stage life sciences company, which engages in the research and development of treatment for cancers, atherosclerosis, and infectious diseases. The company is headquartered in Melbourne, Victoria. The company went IPO on 2010-02-15. The firm is engaged in the research and development of Photosoft technology for the treatment of a range of cancers, atherosclerosis and infectious diseases. The firm is developing Photosoft technology as a Photodynamic Therapy (PDT). PDT uses non-toxic photosensitizers and light to selectively kill cancer cells and promote an anti-cancer immune response. PDT also offers an alternative treatment option aimed at achieving complete tumor regression and long-lasting remission. PDT has also demonstrated broad-spectrum activity across multiple infectious diseases, including bacteria, fungi and viruses. The company holds the Australia and New Zealand license rights and distribution rights to Hong Kong and the rest of Asia Pacific, excluding China, Macau, Taiwan and Japan, to the Photosoft technology for all cancer indications. The Company’s wholly owned subsidiary is Epitech Dermal Science Pty Ltd.

🙌 Performance (5Yr p.a)

-16.36%

📊 Share price

$0.00 AUD

📦 LOGISTICS